Stock Events

Stock Events

Dermata Therapeutics 

$0.02
10
+$0+5.03% Today

Statistics

Day High
0.02
Day Low
0.02
52W High
0.02
52W Low
0.02
Volume
400
Avg. Volume
-
Mkt Cap
16,918.74
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-4.5
-3.12
-1.73
-0.35
Expected EPS
-0.72
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-24.57MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DRMAW. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Aclaris Therapeutics
ACRS
Mkt Cap273M
Aclaris Therapeutics focuses on dermatological treatments, directly competing in Dermata's market space for skin conditions.
AnaptysBio
ANAB
Mkt Cap1.02B
AnaptysBio is involved in developing therapeutic antibodies for inflammatory diseases, including dermatological conditions, making it a direct competitor.
Journey Medical
DERM
Mkt Cap213.64M
Journey Medical Corporation, operating under the ticker DERM, focuses on dermatology, competing in the same therapeutic areas as Dermata.
Sol-Gel Technologies
SLGL
Mkt Cap98.9M
Sol-Gel Technologies develops dermatology products, including for acne and rosacea, directly competing with Dermata's product pipeline.
Moderna
MRNA
Mkt Cap10.61B
Moderna, known for its mRNA technology, is exploring dermatological applications, potentially competing with Dermata in innovative treatments.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical, while focusing on genetic diseases, has interests in skin-related treatments, posing indirect competition.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, with its broad focus on biopharmaceuticals, includes dermatology in its portfolio, competing on some fronts with Dermata.
Pfizer
PFE
Mkt Cap140.15B
Pfizer, a large pharmaceutical company, has a diverse portfolio that includes dermatology, making it a competitor on a broader scale.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals division, offers products for skin health, competing across several dermatological areas.

About

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.
Show more...
CEO
Mr. Gerald T. Proehl
Employees
8
Country
US
ISIN
US2498451168

Listings

XNAS
US
DRMA
XNAS
US
DRMAW
BOATS
BOATS
DRMA.BOATS

0 Comments

Share your thoughts

FAQ

What is Dermata Therapeutics stock price today?▼
The current price of DRMAW is $0.02 USD — it has increased by +5.03% in the past 24 hours. Watch Dermata Therapeutics stock price performance more closely on the chart.
What is Dermata Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Dermata Therapeutics stocks are traded under the ticker DRMAW.
Is Dermata Therapeutics stock price growing?▼
DRMAW stock has fallen by -25.05% compared to the previous week, the month change is a -12.29% fall, over the last year Dermata Therapeutics has showed a +9.21% increase.
What is Dermata Therapeutics market cap?▼
Today Dermata Therapeutics has the market capitalization of 16,918.74
When is the next Dermata Therapeutics earnings date?▼
Dermata Therapeutics is going to release the next earnings report on May 20, 2026.
What were Dermata Therapeutics earnings last quarter?▼
DRMAW earnings for the last quarter are -0.35 USD per share, whereas the estimation was -1.54 USD resulting in a +77.27% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Dermata Therapeutics revenue for the last year?▼
Dermata Therapeutics revenue for the last year amounts to 0 USD.
What is Dermata Therapeutics net income for the last year?▼
DRMAW net income for the last year is -24.57M USD.
How many employees does Dermata Therapeutics have?▼
As of April 02, 2026, the company has 8 employees.
In which sector is Dermata Therapeutics located?▼
Dermata Therapeutics operates in the Health Care sector.
When did Dermata Therapeutics complete a stock split?▼
The last stock split for Dermata Therapeutics was on March 14, 2023 with a ratio of 1:16.
Where is Dermata Therapeutics headquartered?▼
Dermata Therapeutics is headquartered in San Diego, US.